CD19 anticorps

N° du produit ABIN6941098

Détail du produit anti-CD19 anticorps

Antigène: CD19 (CD19 Molecule (CD19))

Reactivité: Humain, Singe

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD19 est non-conjugé

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Purification: Purified by Protein A/G

Immunogène: Recombinant full-length human CD19 protein

Clone: CVID3-155

Isotype: IgG1 kappa

Information d'application

Indications d'application:

Positive Control: Raji cells. Tonsil, Lymph Node or Spleen.

Known Application: Flow Cytometry (1-2 μg/million cells), ,Immunofluorescence (1-2 μg/mL), ,Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur CD19

Antigène: CD19 (CD19 Molecule (CD19))

Autre désignation: CD19 (CD19 Produits)

Synonymes: anticorps B4, anticorps CVID3, anticorps AW495831, anticorps CD19, anticorps CD19 molecule, anticorps CD19 antigen, anticorps CD19, anticorps Cd19

Sujet: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Poids moléculaire: 95kDa

ID gène: 930

UniProt: P15391

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway